RR

1,162.5

-2.47%↓

BATS

4,334

+1.69%↑

BAE

2,110

-1.63%↓

REL

2,438

-1.1%↓

AAL

3,039

+0.76%↑

RR

1,162.5

-2.47%↓

BATS

4,334

+1.69%↑

BAE

2,110

-1.63%↓

REL

2,438

-1.1%↓

AAL

3,039

+0.76%↑

RR

1,162.5

-2.47%↓

BATS

4,334

+1.69%↑

BAE

2,110

-1.63%↓

REL

2,438

-1.1%↓

AAL

3,039

+0.76%↑

RR

1,162.5

-2.47%↓

BATS

4,334

+1.69%↑

BAE

2,110

-1.63%↓

REL

2,438

-1.1%↓

AAL

3,039

+0.76%↑

RR

1,162.5

-2.47%↓

BATS

4,334

+1.69%↑

BAE

2,110

-1.63%↓

REL

2,438

-1.1%↓

AAL

3,039

+0.76%↑

Search

Halma PLC

Suletud

SektorTööstus

3,762 0.86

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3710

Max

3778

Põhinäitajad

By Trading Economics

Sissetulek

107M

187M

Müük

651M

1.2B

P/E

Sektori keskmine

41.717

61.065

Aktsiakasum

0.553

Dividenditootlus

0.61

Kasumimarginaal

15.096

Töötajad

9,000

EBITDA

184M

317M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+9.76% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.61%

2.23%

Järgmine tulemuste avaldamine

11. juuni 2026

Turustatistika

By TradingEconomics

Turukapital

703M

14B

Eelmine avamishind

3761.14

Eelmine sulgemishind

3762

Uudiste sentiment

By Acuity

62%

38%

361 / 406 Pingereas Industrials

Halma PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. märts 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. märts 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. märts 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. märts 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. märts 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. märts 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Global Equities Roundup: Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. märts 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. märts 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. märts 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. märts 2026, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. märts 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. märts 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. märts 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. märts 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. märts 2026, 21:10 UTC

Uudisväärsed sündmused

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. märts 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk
Tulu
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Halma PLC Prognoos

Hinnasiht

By TipRanks

9.76% tõus

12 kuu keskmine prognoos

Keskmine 3,971.25 GBX  9.76%

Kõrge 4,280 GBX

Madal 3,050 GBX

Põhineb 8 Wall Streeti analüütiku instrumendi Halma PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

4

Osta

3

Hoia

1

Müü

Sentiment

By Acuity

361 / 406 Pingereas Tööstus

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Halma PLC

Halma plc, together its subsidiaries, provides technology solutions in the safety, health, and environmental markets in the United States, Mainland Europe, the United Kingdom, the Asia Pacific, Africa, the Middle East, and internationally. It operates through three segments: Safety, Environmental & Analysis, and Healthcare. The Safety segment provides products that protect people, assets and infrastructure, and electrical systems which is used in public and commercial spaces and in industrial and logistics operations. This segment serves Fire Safety, Power Safety, Industrial Safety, and Urban Safety markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; environmental monitoring; analysis of air quality, gases, and water; detection of hazardous gases; and water analysis & treatment systems. It serves the optical analysis, water analysis and treatment, and environmental monitoring markets. The Healthcare segment provides components, devices and systems that provide information and analytics to understand patient health and make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable treatment across clinical specialties, as well as critical fluidic components used by medical diagnostics and original equipment manufacturers. This segment serves the life sciences, health assessment and analytics, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.
help-icon Live chat